GenesWell BCT Patient Guide
8Pages

GenesWell BCT Patient Guide Prognostic Diagnostic Test for Early Stage Breast Cancer Patients (HR+, HER2-)

Have you been diagnosed Stage 1 or 2 Breast Cancer? GenesWell BCT predicts your 10-year metastasis risk to determine the best course of treatment for you. 01 What is GenesWell BCT? GenesWell BCT is a breast cancer prognostic test that provides prognostic information including a forecast for 10-year probability of distant metastasis and survival rate. Depending on your BCT score, you will be classified into HIGH or LOW risk group for distant metastasis. Low risk means that you would have higher survival rate without chemotherapy. On the other hand, high risk would mean that your cancer has...

02 Target patients Stage 1 and 2 early stage breast cancer [vf Hormone receptor positive (ER/PR+) |Vf HER2 negative (HER2-) Fewer than 3 positive lymph nodes (pNO/1) V/ GenesWell BCT score is represented by a number from 0 to 10. Depending on your BCT score, you will be classified into HIGH or LOW risk group for distant metastasis. 4~10 The cancer has a higher risk of recurrence and distant metastasis. The benefits of chemotherapy are likely to be greater than the risks of side effects. 0-3.99 The cancer has a lower risk of recurrence and distant metastasis. The benefits of chemotherapy...

Reflecting Studies show that there are clear racial disparities in breast cancer. While characteristics majority of women throughout Asia-Pacific and South-East Asia diagnosed of Asian patients with breast cancer are estimated to be aged under 50, most of American and European patients are over 50 with menopause.1' GenesWell BCT has been developed with a proven prognostic prediction algorithms that are tailored for Asian patients and reflects the characteristics of Asian breast cancer patients. GenesWell BCT developed and validated with Asian patients (>50% premenopausal) Other tests...

Clinical Study Results Probability of Distant Metastasis Free Survival Rate 2> Low-Risk Group High-Risk Group 73.7% v96.2% Low-Risk Group showed 96.2% distant metastasis free survival rate without receiving chemotherapy treatment. When High-Risk Group is treated with Hormone therapy alone, their 10-year survival rate is only 65.4%. However, combination of Hormone and chemotherapy can increase their survival rate to 91.9%. This means that your 10-year distant metastasis free survival rate can increase up to 26.5% through chemotherapy if you are classified as High-Risk Group. 5) Kwon etal....

Understanding Your GenesWell BCT Result Report Prognostic Diagnostics & Precision Medicine for Breast Cancer Test requested date: report date: ‘ Patient / Sample Information Clinical Information At^ncy- Hospital A Registration No: 123-456-789 Tumor size 2.3 Department SurgicalOncology Recipient PatientA Lymph nodes 0 Doctor DoctorA Sample No: 123 -456 -78 ER Positive Chart No: 123-456-78 Sample collection date: 123 -456 -78 PR Positive Quality Control Positive Control Valid Negative Control Valid W BCT Score BCT Score is the result of analysis based on the level of gene expression of 6...

BCT Score represents the risk of recurrence and metastasis within 10 years after surgery. The higher the score, the greater the risk. A BCT Score of less than 4 points places you in the low-risk group, which means a lower risk of recurrence and distant metastasis within 10 years. On the other hand, a BCT Score of 4 points or more places you in the high-risk group with higher risk of recurrence and distant metastasis within 10 years. Probability of Distant Metastasis within 10-years. Low-risk groups have a low probability of distant metastasis and would be less likely to benefit from...

I Contact us Homepage geneswellbct.com Tel. +82 70-7443-9523